About us

Our ultimate goal is to reach new standards of care, by supporting optimal management of health conditions, which affect a growing population of patients and put extra burden on already stretched health systems.

Throughout our 164-year history, we have set our sights on the most serious and challenging diseases. We seek  breakthrough innovations that have the power to help patients prevail over serious diseases like cancer and diseases of the heart, the immune system, and the blood. ​

With a global investment in R&D of $11.4 billion in 2021, our company steadily advances in the discovery and development of new medicines. We have a diverse and promising pipeline in development across 40 disease areas in Europe.
At Bristol Myers Squibb, we are inspired by a single vision – transforming patients’ lives through science, delivering life changing, innovative medicines that address unmet medical needs of patients with serious diseases.  
Our mission
 

To discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.
 

Our passion
 

Our commitment to continuous learning helps us deliver exceptional results.

 

Inclusion
 

We promote diversity and an environment in which we can all cooperate fully.

Our vision
 

To be the leading biopharmaceutical company changing patients' lives through science.
 

Innovation
 

We work on pioneering solutions for patients.


 

Urgency
 

Together we move forward with speed and quality because patients are waiting.

Our values
 

 Passion, innovation, urgency, responsibility, inclusion and integrity are the foundation of our work and bring us together.

Integrity
 

We put ethics, integrity and quality at the forefront of everything we do for patients, customers and colleagues.

Responsibility
 

We are all part of the success of BMS, we are transparent and we keep our promises.

Facts

Since 1887, BMS has enabled positive change for patients in Europe and around the world.

In Europe, BMS employs more than 6,800 people. 60% of them are women.

By 2050, we have set a global goal to achieve net-zero emissions in scopes one, two and three.

We are proud of the scientific advancements we have made in oncology, hematology, immunology, neuroscience and cardiovascular disease.

We are driving continued innovation across disease areas based on differentiated research platforms that include cell therapy and targeted protein degradation.